ECSP22016558A - Proteínas de fusión terapéuticas - Google Patents

Proteínas de fusión terapéuticas

Info

Publication number
ECSP22016558A
ECSP22016558A ECSENADI202216558A ECDI202216558A ECSP22016558A EC SP22016558 A ECSP22016558 A EC SP22016558A EC SENADI202216558 A ECSENADI202216558 A EC SENADI202216558A EC DI202216558 A ECDI202216558 A EC DI202216558A EC SP22016558 A ECSP22016558 A EC SP22016558A
Authority
EC
Ecuador
Prior art keywords
acute
fusion proteins
chronic
therapeutic fusion
injuries
Prior art date
Application number
ECSENADI202216558A
Other languages
English (en)
Inventor
Laurent Klein
Darko Skegro
Marco Villani
Karl Welzenbach
Sebastien Irigaray
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67875416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP22016558(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP22016558A publication Critical patent/ECSP22016558A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Computer Networks & Wireless Communication (AREA)

Abstract

La presente invención se refiere a proteínas de fusión adecuadas para su uso como medicamento o herramienta de investigación. Los usos terapéuticos de las proteínas de fusión pueden incluir la prevención o el tratamiento de trastornos inflamatorios agudos o crónicos y microvasculares y de órganos impulsados por el sistema inmunitario, por ejemplo, lesión renal aguda, infarto agudo de miocardio, dificultad respiratoria aguda o enfermedad pulmonar obstructiva crónica, fibrosis y otras lesiones de órganos resultantes de traumatismos de tejidos y lesiones agudas y crónicas.
ECSENADI202216558A 2019-09-06 2022-03-04 Proteínas de fusión terapéuticas ECSP22016558A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19196045 2019-09-06

Publications (1)

Publication Number Publication Date
ECSP22016558A true ECSP22016558A (es) 2022-04-29

Family

ID=67875416

Family Applications (2)

Application Number Title Priority Date Filing Date
ECSENADI202216180A ECSP22016180A (es) 2019-09-06 2022-03-03 Proteínas de fusión terapéuticas
ECSENADI202216558A ECSP22016558A (es) 2019-09-06 2022-03-04 Proteínas de fusión terapéuticas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ECSENADI202216180A ECSP22016180A (es) 2019-09-06 2022-03-03 Proteínas de fusión terapéuticas

Country Status (22)

Country Link
US (3) US20230220048A1 (es)
EP (3) EP4025239A1 (es)
JP (4) JP2022547051A (es)
KR (3) KR20220058588A (es)
CN (8) CN118667031A (es)
AR (2) AR119905A1 (es)
AU (3) AU2020340618B2 (es)
BR (2) BR112022003745A2 (es)
CA (3) CA3152990A1 (es)
CO (2) CO2022002567A2 (es)
CR (2) CR20220089A (es)
CU (2) CU20220015A7 (es)
EC (2) ECSP22016180A (es)
IL (3) IL290618A (es)
JO (2) JOP20220055A1 (es)
MX (2) MX2022002638A (es)
MY (1) MY208682A (es)
PE (2) PE20220401A1 (es)
PH (2) PH12022550539A1 (es)
TW (2) TW202122414A (es)
WO (3) WO2021044362A1 (es)
ZA (2) ZA202201827B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020084344A2 (en) * 2018-10-25 2020-04-30 Nexel Co., Ltd. Compositions and methods for treating or preventing fibrosis
CN118076371A (zh) 2021-04-22 2024-05-24 百进生物科技公司 用于检测和耗竭磷脂酰丝氨酸阳性细胞的磷脂酰丝氨酸结合剂
KR102801198B1 (ko) * 2021-06-28 2025-04-30 (주) 넥셀 특발성 폐섬유증 예방 또는 치료용 폴리펩타이드 및 이를 포함하는 약학 조성물
CN114288386B (zh) * 2022-01-25 2023-12-12 华中科技大学同济医学院附属协和医院 Del-1作为炎症性肠病新的生物标志物及治疗药物应用
TW202417520A (zh) * 2022-10-14 2024-05-01 南韓商伊米斯療法股份有限公司 融合分子和治療免疫性疾病的方法
WO2025086968A1 (zh) * 2023-10-25 2025-05-01 上海萨美细胞技术有限公司 一种用于治疗肺纤维化的药物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP2990417A1 (en) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin insulin fusion protein
EP1888096B1 (en) 2005-05-13 2017-12-27 The Feinstein Institute for Medical Research Milk fat globule epidermal growth factor-factor viii and sepsis
CN101511866A (zh) * 2006-09-08 2009-08-19 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
EP2215264B1 (en) 2007-11-15 2015-04-01 The Feinstein Institute for Medical Research Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8
RU2607374C2 (ru) 2009-10-30 2017-01-10 Новозаймс Байофарма Дк А/С Варианты альбумина
EP2536756B1 (en) 2010-02-16 2018-04-25 MedImmune, LLC Hsa-related compositions and methods of use
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
EP2635598A1 (en) 2010-11-01 2013-09-11 Novozymes Biopharma DK A/S Albumin variants
AU2012212047A1 (en) * 2011-02-03 2013-08-22 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
JP2014510518A (ja) 2011-02-15 2014-05-01 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法
EP2701730A4 (en) * 2011-04-28 2015-05-27 The Feinstein Inst Medical Res MFG-E8 AND USES THEREOF
KR20140027307A (ko) 2011-05-05 2014-03-06 노보자임스 바이오파마 디케이 에이/에스 알부민 변이체
WO2013049200A1 (en) * 2011-09-26 2013-04-04 University Of Louisville Research Foundation, Inc. Methods of treating periodontal inflammation and periodontal bone loss
CN105452290A (zh) 2012-11-08 2016-03-30 诺维信生物制药丹麦公司 白蛋白变体
AU2014217831A1 (en) 2013-02-16 2015-07-16 Albumedix Ltd. Pharmacokinetic animal model
WO2015025959A1 (ja) 2013-08-23 2015-02-26 独立行政法人理化学研究所 蛍光特性を示すポリペプチド、およびその利用
CN106537795B (zh) * 2014-03-31 2021-10-01 英国电讯有限公司 数据通信
EP4464332A1 (en) * 2014-03-31 2024-11-20 Hanmi Pharm. Co., Ltd. Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage
WO2015175512A1 (en) * 2014-05-15 2015-11-19 The Trustees Of The University Of Pennsylvania Compositions and methods of regulating bone resorption
KR20170013621A (ko) 2015-07-28 2017-02-07 (주) 넥셀 Ｍｉｌｋ ｆａｔ ｇｌｏｂｕｌｅ－ＥＧＦ ｆａｃｔｏｒ（ＭＦＧ－Ｅ８）을 이용한 조직섬유화 예방 또는 치료용 조성물
CN115960249A (zh) * 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
EP3589650A1 (en) * 2017-03-02 2020-01-08 Novartis AG Engineered heterodimeric proteins
US11028139B2 (en) 2017-05-17 2021-06-08 Nexel Co., Ltd. Recombinant protein for preventing or treating tissue fibrosis and composition for preventing or treating tissue fibrosis comprising the same
WO2020084344A2 (en) 2018-10-25 2020-04-30 Nexel Co., Ltd. Compositions and methods for treating or preventing fibrosis

Also Published As

Publication number Publication date
PE20221051A1 (es) 2022-06-30
CO2022002545A2 (es) 2022-04-08
KR20220058586A (ko) 2022-05-09
CR20220096A (es) 2022-05-11
WO2021044362A1 (en) 2021-03-11
CU20220015A7 (es) 2022-10-11
WO2021044361A1 (en) 2021-03-11
US20230265160A1 (en) 2023-08-24
AR119905A1 (es) 2022-01-19
AU2020343926B2 (en) 2024-11-21
CN114341195B (zh) 2025-04-25
AU2020340618A1 (en) 2022-04-07
MX2022002637A (es) 2022-03-25
JOP20220058A1 (ar) 2023-01-30
ZA202201827B (en) 2023-11-29
PH12022550539A1 (en) 2023-03-20
CN114341194A (zh) 2022-04-12
CA3152499A1 (en) 2021-03-11
CA3152990A1 (en) 2021-03-11
MY208682A (en) 2025-05-23
CO2022002567A2 (es) 2022-04-08
CN118909136A (zh) 2024-11-08
EP4025239A1 (en) 2022-07-13
EP4025238A1 (en) 2022-07-13
CU20220016A7 (es) 2022-10-11
AU2020343926A1 (en) 2022-04-07
CN114302896A (zh) 2022-04-08
ECSP22016180A (es) 2022-04-29
JP2022547051A (ja) 2022-11-10
TW202122414A (zh) 2021-06-16
TWI873177B (zh) 2025-02-21
JOP20220055A1 (ar) 2023-01-30
WO2021044360A1 (en) 2021-03-11
CN118812727A (zh) 2024-10-22
KR20220058588A (ko) 2022-05-09
IL290660A (en) 2022-04-01
PH12022550538A1 (en) 2023-03-20
CN118772293A (zh) 2024-10-15
IL290675A (en) 2022-04-01
CN118667031A (zh) 2024-09-20
US20230308835A1 (en) 2023-09-28
BR112022003745A2 (pt) 2022-05-31
AR119902A1 (es) 2022-01-19
ZA202201828B (en) 2023-10-25
JP2022547111A (ja) 2022-11-10
CN119285791A (zh) 2025-01-10
JP2022547050A (ja) 2022-11-10
IL290618A (en) 2022-04-01
JP2025124629A (ja) 2025-08-26
AU2020343512A1 (en) 2022-04-07
MX2022002638A (es) 2022-03-25
BR112022003762A2 (pt) 2022-05-31
KR20220058585A (ko) 2022-05-09
US20230220048A1 (en) 2023-07-13
AU2020340618B2 (en) 2025-01-23
TW202122415A (zh) 2021-06-16
PE20220401A1 (es) 2022-03-22
CR20220089A (es) 2022-03-30
JP7671739B2 (ja) 2025-05-02
EP4025237A1 (en) 2022-07-13
CN114341195A (zh) 2022-04-12
CA3152500A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
ECSP22016558A (es) Proteínas de fusión terapéuticas
CY1123391T1 (el) (2s)-n-[(1s)-1-kyano-2-φainyλaιθyλ]-1,4-oξazeπan-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης ι
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
CL2019002103A1 (es) Derivados de tirosinamida como inhibidores de rho-quinasa.
EP4342540A3 (en) Substituted heterocyclyl derivatives as cdk inhibitors
EP3784213C0 (en) SUSTAINED-RELEASE INHALABLE LIPOSOMAL COMPOSITION FOR THE TREATMENT OF PULMONARY DISEASES
EA201400392A1 (ru) ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb
CL2008001593A1 (es) Compuestos derivados de heterociclos, antagonistas para el ccr2; y uso de los compuestos para tratar afecciones o enfermedades del tracto respiratorio, como enfermedad pulmonar obstructiva cronica y asma.
MX2018013002A (es) Moduladores de la proteina reguladora de la conductancia transmembrana de la fibrosis quistica.
EA201891374A1 (ru) Замещенные 2-фенил-3-(пиперазинметил)имидазопиридины и их применение
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
EA202090043A1 (ru) Диазабициклические замещенные имидазопиримидины и их применение
CY1123011T1 (el) Θεραπευτικη χρηση οστικων μορφογενετικων πρωτεϊνων
HUE060322T2 (hu) Belélegezhetõ készítmények tüdõbetegségek kezelése során történõ alkalmazásra
AR085056A1 (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion
RU2017124487A (ru) НОВЫЙ ПЕПТИД-ИНГИБИТОР PI3Kγ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ОРГАНОВ ДЫХАНИЯ
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
UY28589A1 (es) Nuevas sales de tiotropio, procedimientos para su preparación , así como formulaciones medicamentosas que las contienen
CL2017000117A1 (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrófila.
AR062582A1 (es) Variedades polimorficas de derivados de 1-azonia-biciclo-[2.2.2]-octano
TH2001002258A (th) องค์ประกอบของฟอสโฟไรเลทเทาเพบไทด์และการใช้ของมัน
EA201791798A1 (ru) Фармацевтические композиции, включающие n-(3,5-диметоксифенил)-n'-(1-метилэтил)-n-[3-(1-метил-1h-пиразол-4-ил)хиноксалин-6-ил]этан-1,2-диамин
BR112017008790A2 (pt) cromanos substituídos e métodos de uso
BR112015025619A2 (pt) sistema de expressão para administração sistêmica, e, composição farmacêutica
TH167851A (th) (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค